IOVA Iovance Biotherapeutics Inc
Company Analysis
Latest News
Iovance's Lung Cancer Bet Sparked a 13% After-Hours Pop — But Will the Full Data Survive the Market's Scrutiny?
Shares of Iovance Biotherapeutics surged 13.4% to $16.79 in after-hours trading on October 28 after the company teased positive results from its lung cancer...
🔴 Iovance Biotherapeutics is trading 12% down today after updated Phase 2 lung-cancer results
Iovance Biotherapeutics is trading 11.98% down at $8.36 after updated Phase 2 lung-cancer results. - The study reported a 24.6% response rate among 69...
🔴 Iovance Biotherapeutics is trading 4.1% down in pre-market after updated results showed a lower response rate
Iovance Biotherapeutics is trading 4.1% lower at $9.17 in pre-market after updated lung cancer results showed a 24.6% overall response rate, versus 25.6%...
Iovance Announces New Lung Cancer Strategy After Trial Shows 59.1% ORR in Biomarker Group
Iovance Biotherapeutics announced updated results from its Phase 2 IOV-LUN-202 trial for its TIL therapy, lifileucel, in metastatic non-small-cell lung cancer...
🔴 Iovance Biotherapeutics is trading 25.39% down today after Phase 2 results matched prior response data
Iovance Biotherapeutics is trading at $11.05, down 25.39%, after updated Phase 2 lung-cancer results showed a 24.6% response rate in 69 patients, consistent...
🔴 Iovance Biotherapeutics is trading 12.09% down in pre-market
Iovance Biotherapeutics is trading at $13.02 with a -12.09% pre-market move on October 29; the broader market is weaker, but no clear catalyst is confirmed. -...
🔴 Iovance Biotherapeutics is trading 8.85% down in pre-market
Iovance Biotherapeutics is trading 8.85% lower at $13.50, compared with its October 28 close of $14.81; available news does not establish a clear reason for...
🟢 Iovance Biotherapeutics is trading 10.74% up in pre-market after positive Phase 2 lifileucel data
Iovance Biotherapeutics is trading at $16.40, up 10.74%, after announcing positive Phase 2 registrational-cohort results for lifileucel in previously treated...
🟢 Iovance Biotherapeutics is trading 13.37% up in after-hours trading after positive lifileucel results in metastatic NSCLC
Iovance Biotherapeutics is trading 13.37% higher at $16.79 after announcing positive results from Phase 2 registrational cohorts of lifileucel in previously...
🟢 Iovance Biotherapeutics is trading 9.45% up in after-hours trading — no confirmed company-specific catalyst
Iovance Biotherapeutics is trading up 9.45% in after-hours trading at $16.21, with no confirmed company-specific announcement explaining the move. - The...
🟢 Iovance Biotherapeutics is trading 4.64% up with no clear company-specific catalyst confirmed
Iovance Biotherapeutics is trading at $14.42, up 4.64%, during October 27, 2026 trading, with no clear company-specific catalyst confirmed for the rise. - The...
🔴 Iovance Biotherapeutics is trading 4.40% down
Iovance Biotherapeutics is trading 4.40% down at $13.47 on October 26, 2026; no clear downside catalyst has been confirmed. - Shares declined despite broad...
🔴 Iovance Biotherapeutics is trading 4.17% down on October 22, 2026, amid AI-spending and oil-price concerns
Iovance Biotherapeutics is trading 4.17% lower at $14.01 as markets weakened on October 22; available reporting showed no clear company-specific catalyst. -...
🟢 Iovance Biotherapeutics is trading 4.19% up today amid biotech-sector gains
Iovance Biotherapeutics is trading 4.19% higher at $14.80, with biotech-sector strength offering a possible tailwind. - No verified company announcement dated...
🟢 Iovance Biotherapeutics is trading 7% up
Iovance Biotherapeutics is trading at $14.55, up 6.83%; no verified October 19 company announcement clearly explains the rise. - The latest company...
🔴 Iovance Biotherapeutics is trading 4.62% down today amid broader biotech-sector weakness
Iovance Biotherapeutics is trading 4.62% down at $14.04, with the move consistent with broader biotech-sector weakness. - No credible company-specific...
Iovance's Melanoma Therapy Shows Promise and Revenue Surges — But Can This Cash-Burning Biotech Reach Profitability Before the Money Runs Out?
Reports emerged that Iovance Biotherapeutics delivered a 41% response rate for its immune-cell cancer therapy in a key melanoma trial, while simultaneously...
Iovance Reports 41% Response Rate for Lifileucel in Melanoma Trial
Iovance Biotherapeutics reported positive interim results from its Phase 2 IOV-COM-202 study of lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, in...
🟢 Iovance Biotherapeutics is trading 12% up
Iovance Biotherapeutics is trading 11.76% higher at $14.88 on October 9, 2026, with no clear company-specific announcement identified to explain the move. -...
🟢 Iovance Biotherapeutics is trading 5% up
Iovance Biotherapeutics is trading at $13.94, up 4.73% at 9:59 a.m. ET on October 9, 2026; no clear company-specific catalyst was identified for the rise. -...